Alzinova ABFNSE Alzinova Stock Report

Alzinova AB engages in the research and development of drugs for treatment of Alzheimer's disease. The company is headquartered in Moelndal, Vastra Gotalands. The company went IPO on 2015-11-25. The firm is engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease. The firm focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.